Table 3.
Diagnostic criteria of tested parameters and in combined analysis with CA 125 and SCC-Ag in cervical cancer patients
| Tested parameters | Diagnostic criteria (%) | Cervical cancer | |||
|---|---|---|---|---|---|
| Stage I | Stage II | Stages III and IV | Total | ||
| M-CSF | SE | 51.72 | 75.00 | 78.13 | 69.41 |
| SP | 86.00 | 86.00 | 86.00 | 86.00 | |
| MMP-2 | SE | 93.10 | 82.76 | 96.88 | 92.05 |
| SP | 58.00 | 58.00 | 58.00 | 58.00 | |
| TIMP-2 | SE | 17.24 | 17.86 | 59.38 | 32.18 |
| SP | 60.00 | 60.00 | 60.00 | 60.00 | |
| CA 125 | SE | 62.07 | 82.14 | 96.88 | 80.00 |
| SP | 68.00 | 68.00 | 68.00 | 68.00 | |
| SCC-Ag | SE | 75.86 | 78.57 | 78.13 | 81.18 |
| SP | 74.00 | 74.00 | 74.00 | 74.00 | |
| M-CSF + CA 125 | SE | 79.31 | 93.10 | 100.00 | 91.76 |
| SP | 66.00 | 66.00 | 66.00 | 66.00 | |
| MMP-2 + CA 125 | SE | 96.55 | 100.00 | 100.00 | 98.88 |
| SP | 30.00 | 30.00 | 30.00 | 30.00 | |
| TIMP-2 + CA 125 | SE | 68.97 | 85.71 | 100.00 | 85.39 |
| SP | 28.00 | 28.00 | 28.00 | 28.00 | |
| M-CSF + SCC-Ag | SE | 86.21 | 92.86 | 93.75 | 91.76 |
| SP | 66.00 | 66.00 | 66.00 | 66.00 | |
| MMP-2 + SCC-Ag | SE | 96.55 | 96.43 | 100.00 | 96.63 |
| SP | 36.00 | 36.00 | 36.00 | 36.00 | |
| TIMP-2 + SCC-Ag | SE | 75.86 | 79.31 | 87.50 | 82.02 |
| SP | 30.00 | 30.00 | 30.00 | 30.00 | |
Abbreviations: CA, cancer antigen; MMP-2, matrix metalloproteinase-2; TIMP-2, tissue inhibitor of metalloproteinase-2; M-CSF, macrophage-colony stimulating factor; SE, sensitivity; SP, Specificity